Alentis raises €60.3M Series B round
15 June 2021· Allschwil, Switzerland· health, oncology, biotech, b2b, deep_hardware
The round was raised to fund proof-of-concept clinical trials for ALE.F02 in advanced liver and kidney fibrosis and to support drug discovery programs for other fibrotic diseases and hepatobiliary cancers.
Investors
LeadMorningside Venture Investments
Also participating
BpifranceHigh-Tech GründerfondsSchroders CapitalBioMedPartnersJeito CapitalBB Pureos Bioventures
About Alentis
Stage
Series D
Headquarters
Allschwil, Switzerland
Founded
2019
Team Size
51–200
Sectors
healthoncologybiotechb2bdeep_hardware